![]() |
|
|
Vol. 30, Issue 12, 1484-1490, December 2002
Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan
| |
Abstract |
|---|
|
|
|---|
The nicotine and cotinine N-glucuronidations in human liver microsomes were characterized. The Eadie-Hofstee plots of nicotine N-glucuronidation in human liver microsomes were clearly biphasic, indicating the involvement of multiple enzymes. The apparent Km and Vmax values were 33.1 ± 28.1 µM and 60.0 ± 21.0 pmol/min/mg and 284.7 ± 122.0 µM and 124.0 ± 44.0 pmol/min/mg for the high- and low-affinity components, respectively, in human liver microsomes (n = 4). However, the Eadie-Hofstee plots of cotinine N-glucuronidation in human liver microsomes were monophasic (apparent Km = 1.9 ± 0.3 mM, Vmax = 655.6 ± 312.3 pmol/min/mg). The nicotine and cotinine N-glucuronidations in the recombinant human UDP-glucuronosyltransferases (UGTs) (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) expressed in baculovirus-infected insect cells or human B-lymphoblastoid cells that are commercially available were determined. However, no recombinant UGT isoforms showed detectable nicotine and cotinine N-glucuronides (the concentrations of nicotine and cotinine were 0.5 and 2 mM, respectively). Nicotine and cotinine N-glucuronidations in pooled human liver microsomes were competitively inhibited by bilirubin as a substrate for UGT1A1 (Ki = 3.9 and 3.3 µM), imipramine as a substrate for UGT1A4 (Ki = 6.1 and 2.7 µM), and propofol as a substrate for UGT1A9 (Ki = 6.0 and 12.0 µM). The nicotine N-glucuronidation (50 µM nicotine) in 14 human liver microsomes was significantly (r = 0.950, P < 0.0001) correlated with the cotinine N-glucuronidation (0.2 mM cotinine), indicating that the same isoform(s) is involved in both glucuronidations. Furthermore, weak correlations between imipramine N-glucuronidation and nicotine N-glucuronidation (r = 0.425) or cotinine N-glucuronidation (r = 0.517) were observed. In conclusion, the involvement of UGT1A1 and UGT1A9 as well as UGT1A4 in nicotine and cotinine N-glucuronidations in human liver microsomes was suggested, although the contributions of each UGT isoform could not be determined conclusively.
| |
Introduction |
|---|
|
|
|---|
Nicotine is mainly metabolized
to cotinine by CYP2A6 in human livers (Nakajima et al., 1996a
), and
cotinine is further metabolized to trans-3'-hydroxycotinine
by CYP2A6 (Nakajima et al., 1996b
). Nicotine and cotinine have been
used to assess nicotine intake in smokers and nonsmokers (Kyerematen et
al., 1990
; Benowitz et al., 1994
). Although 81 to 98% of the nicotine
absorbed from tobacco smoking is recovered in the urine as nicotine and
its metabolites (Kyerematen et al., 1990
), urinary nicotine and
cotinine account for only 10 to 40% of the nicotine absorbed (Neurath
et al., 1988
). Glucuronidation is an important pathway of nicotine
metabolism in humans. The average percentages of nicotine
N-glucuronide and cotinine N-glucuronide excreted
in smoker's urine were approximately 3 to 4% and 9 to 17% of
nicotine absorbed, respectively (Curvall et al., 1991
; Byrd et al.,
1992
; Benowitz et al., 1994
).
In humans, there are large interindividual differences in nicotine
metabolism (Cholerton et al., 1994
; Benowitz et al., 1995
). Recently,
we reported that the genetic polymorphism of CYP2A6 affects the
cotinine formation from nicotine (Kwon et al., 2001
; Nakajima et al.,
2001
). Similarly, the metabolic pathway of glucuronidation would be one
of the causal factors for the interindividual differences in nicotine
metabolism. Indeed, considerable interindividual variability in the
percentages of the conjugates of nicotine (3.8-56.0%) and cotinine
(0-60.3%) in urine has been reported (Benowitz et al., 1994
). It has
also been reported that nicotine and cotinine
N-glucuronidations seemed to be polymorphic in
African-Americans, although they were unimodal in Caucasians (Benowitz
et al., 1999
).
Glucuronidation is catalyzed by UDP-glucuronosyltransferases
(UGTs1) (Miners and
Mackenzie, 1991
). It is well known that there are many isoforms of
mammalian UGT enzymes (Tukey and Strassburg, 2000
). To date, two UGT
families have been identified in humans: UGT1 and UGT2. The
UGT1 and UGT2 genes seem to be structurally different in that UGT1 proteins result from alternate splicing of
different first exons with five shared exons encoded by the UGT1 gene
complex, whereas UGT2 proteins seem to be encoded by unique genes. In
the human genome, at least 13 different first exons have been
identified for the UGT1 gene (Gong et al., 2001
). Five of these human
UGT1A isoforms, UGT1A1, UGT1A3, UGT1A4, UGT1A6, and UGT1A9, are
expressed in the liver (Strassburg et al., 1999
). In general, it is
known that only human UGT1A3 and UGT1A4 catalyze the
N-glucuronidation of tertiary amines, such as imipramine, amitriptyline, and chlorpromazine, to form quaternary ammonium glucuronides (Green et al., 1995
; Green and Tephly, 1998
). Quaternary ammonium glucuronides are formed from nicotine and cotinine. However, the UGT isoforms that catalyze the nicotine and cotinine
glucuronidations have not been determined. Therefore, the purpose of
the present study is to identify the human UGT isoform involved in
nicotine and cotinine N-glucuronidations. Previously, we
established a highly sensitive HPLC-UV method for directly determining
nicotine N-glucuronide and cotinine N-glucuronide
(Nakajima et al., 2002a
). We applied this method for determining the
N-glucuronosyltransferase activities of nicotine and
cotinine in human liver microsomes.
| |
Materials and Methods |
|---|
|
|
|---|
Materials.
(S)-Nicotine, (S)-cotinine, UDP-glucuronic acid,
alamethicin, and estradiol were purchased from Sigma-Aldrich (St.
Louis, MO). Nicotine N-
-glucuronide and cotinine
N-
-glucuronide were purchased from Toronto Research
Chemicals (Toronto, ON, Canada). 4-Nitrophenol, imipramine
hydrochloride, and bilirubin were from Wako Pure Chemicals (Osaka,
Japan). Morphine hydrochloride was purchased from Tekeda Chemical
Industries (Osaka, Japan). Propofol was kindly supplied by AstraZeneca
(London, UK). Pooled human liver microsomes (H161) and microsomes from
14 individual human livers (H003, H006, H023, H030, H042, H043, H056,
H066, H070, H089, H093, H112, HK23, and HK34) were purchased from
Gentest (Woburn, MA). The glucuronosyltransferase activities of
estradiol, trifluoperazine, and propofol as typical activities for
UGT1A1, UGT1A4, and UGT1A9, respectively, in these human liver
microsomes except for H161, H006, H030, and H070 were provided by the
manufacturer. Recombinant human UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A8,
UGT1A9, UGT1A10, UGT2B7, and UGT2B15 expressed in baculovirus-infected insect cells (Supersomes) were from Gentest. Recombinant UGT1A1, UGT1A4, UGT1A6, and UGT1A9 expressed in human B-lymphoblastoid cells
were also from Gentest. Recombinant UGT1A1, UGT1A3, UGT1A6, UGT1A7,
UGT1A10, and UGT2B7 expressed in baculovirus-infected insect cells
(Baculosomes) were from PanVera (Madison, WI). All other chemicals and
solvents were of the highest grade commercially available.
Nicotine and Cotinine N-Glucuronidation Assays.
These assays were previously established in our laboratory (Nakajima et
al., 2002a
). Briefly, a typical incubation mixture (200 µl of total
volume) contained 20 mM Tris-HCl buffer, pH 7.4, 5 mM
MgCl2, 2.5 mM UDP-glucuronic acid, 25 µg/ml
alamethicin, 0.25 mg/ml human liver microsomes, and 50 µM nicotine or
0.2 mM cotinine. For recombinant UGTs, 0.5 mg/ml microsomes and 0.5 mM nicotine or 2 mM cotinine were included. The reactions were initiated by the addition of UDP-glucuronic acid and were then incubated at
37°C for 60 min. The reactions were terminated by boiling for 10 min.
After removal of the protein by centrifugation at 10,000 rpm for 5 min,
a 2-µl solution containing phosphoric acid and heptane sulfonate
sodium for nicotine N-glucuronide or octane sulfonate sodium
for cotinine N-glucuronide was added to make the
concentrations of these chemicals the same as those in the mobile
phases. A 20-µl portion of the sample was subjected to HPLC.
Chromatography was performed using an L-7100 pump (Hitachi, Tokyo,
Japan), an L-7400 UV detector (Hitachi), an L-7200 autosampler (Hitachi), an L-7500 integrator (Hitachi), and an 865-CO column oven
(Jasco, Tokyo, Japan) with a Capcell Pak C18
UG120 (4.6 × 250 mm; 4 µm) column (Shiseido, Tokyo, Japan). The
flow rate was 1.0 ml/min and the column temperature was 35°C. The
eluent was monitored at 260 nm with a noise-base clean Uni-3 (Union,
Gunma, Japan). The Uni-3 can reduce the noise by integration of the
output and increase the signal 3-fold by differentiation of the output and 5-fold by further amplification with an internal amplifier, resulting in a maximum 15-fold amplification of the signal. The mobile
phases were 3% CH3OH, 2 mM
NaH2PO4, 0.2% phosphoric
acid, and 4 mM heptane sulfonate sodium for the determination of the nicotine N-glucuronide, and 1% CH3OH,
2 mM NaH2PO4, 0.1%
phosphoric acid, and 5 mM octane sulfonate sodium for the determination
of the cotinine N-glucuronide. The quantification of
nicotine N-glucuronide or cotinine N-glucuronide
was performed by comparing the HPLC peak heights to those of authentic standards.
Kinetic Analyses of Nicotine and Cotinine N-Glucuronidations in Human Liver Microsomes. Kinetic parameters were determined with the assays described above. The concentrations of nicotine and cotinine were 25 µM to 1 mM and 50 µM to 10 mM, respectively. Kinetic parameters (apparent Km and Vmax) were estimated by analyzing the Eadie-Hofstee plots.
Inhibition Analysis of Nicotine and Cotinine
N-Glucuronidations in Human Liver Microsomes.
Six compounds were tested for their inhibitory effects on the nicotine
and cotinine N-glucuronidations in pooled human liver microsomes. Bilirubin is a typical substrate for UGT1A1 (Bosma et al.,
1994
; Senafi et al., 1994
). Estradiol is a substrate for UGT1A1 (and
UGT1A9 as a minor enzyme) (Bosma et al., 1994
; Senafi et al.
, Hanioka
et al., 2001b
). 4-Nitrophenol is a substrate for UGT1A6 and UGT1A9
(Hanioka et al., 2001a
,b
). Imipramine is a substrate for UGT1A4 (and
UGT1A3 as a minor enzyme) (Green et al., 1995
, 1998
; Green and Tephly,
1998
). Propofol is a specific substrate for UGT1A9 (McGurk et al.,
1998
; Hanioka et al., 2001b
). Morphine is a typical substrate for
UGT2B7 (Coffman et al., 1997
). Furthermore, the inhibitory effects of
cotinine on nicotine N-glucuronidation and those of nicotine
on cotinine N-glucuronidation in human liver microsomes were
also determined. For the determination of the IC50 values, the concentrations of nicotine and
cotinine were set at 50 µM and 0.2 mM, respectively. For
determination of the Ki values, the
concentrations of nicotine and cotinine were 50 to 500 µM and 0.3 to
10 mM, respectively. The Lineweaver-Burk plot and Dixon plot were
adopted to determine the Ki value and the inhibitory type. Bilirubin and 4-nitrophenol were dissolved in
dimethyl sulfoxide and ethanol, respectively. Estradiol and propofol were dissolved in methanol. Imipramine hydrochloride and
morphine hydrochloride were dissolved in water. The final concentration
of the organic solvents in the reaction mixture was <1% (v/v).
Imipramine Glucuronidation Assay.
The assay was previously established in our laboratory (Nakajima et
al., 2002c
). Briefly, a typical incubation mixture (200 µl of total
volume) contained 50 mM Tris-HCl buffer, pH 7.4, 5 mM
MgCl2, 5 mM UDP-glucuronic acid, 25 µg/ml
alamethicin, 0.25 mg/ml human liver microsomes, and 0.5 mM imipramine.
The reactions were initiated by the addition of UDP-glucuronic acid and
were then incubated at 37°C for 60 min. The reactions were terminated by boiling for 10 min. After removal of the protein by centrifugation at 10,000 rpm for 5 min, a 20-µl portion of the sample was subjected to HPLC. The instruments of HPLC were described above. Chromatographic separations were performed on a Mightysil RP-18 (4.6 × 150 mm; 5 µm) column (Kanto Chemical, Tokyo, Japan). The flow rate was 0.5 ml/min and the column temperature was 35°C. The eluent was monitored
at 205 nm. The mobile phases were 35% CH3CN, 50 mM KH2PO4, pH 4.0. The
retention times of imipramine N-glucuronide and imipramine were 6.2 and 15.4 min, respectively. The peak of imipramine
N-glucuronide was confirmed by liquid
chromatography-mass/mass spectrometry analysis (Nakajima et al.,
2002c
).
Correlation Analyses. Correlations between Nicotine N-glucuronidation and cotinine N-glucuronidations, and the other glucuronidation activities were determined by Pearson's product-moment method. A P value of less than 0.05 was considered statistically significant.
| |
Results |
|---|
|
|
|---|
Kinetic Parameters of Nicotine and Cotinine N-Glucuronidations in Human Liver Microsomes. Kinetic analyses were performed using pooled human liver microsomes (H161) and representative liver microsomes from four humans (H003, H030, H042, and H112). The Eadie-Hofstee plots for nicotine N-glucuronidation in all human liver microsomes examined in this study were clearly biphasic. A representative plot is shown in Fig. 1A. The apparent Km values were 33.1 ± 28.1 and 284.7 ± 122.0 µM for the high- and low-affinity components, respectively, in the liver microsomes from four humans (Table 1). The apparent Vmax values were 60.0 ± 21.0 and 124.0 ± 44.0 pmol/min/mg for the high- and low-affinity components, respectively, in the liver microsomes from four humans. Similar kinetic parameters were obtained also with the pooled human liver microsomes. In contrast, the Eadie-Hofstee plots for cotinine N-glucuronidation in all human liver microsomes were monophasic (Fig. 1B). The apparent Km and Vmax values were 1.9 ± 0.3 mM and 655.6 ± 312.3 pmol/min/mg, respectively, in the liver microsomes from four humans (Table 2). Similar values were also obtained with the pooled human liver microsomes.
|
|
|
Nicotine and Cotinine N-Glucuronidations in Recombinant Human UGT Isoforms. All recombinant UGT isoforms expressed in human B-lymphoblastoid cells or baculovirus-infected insect cells that are commercially available were used to determine their nicotine and cotinine N-glucuronosyltransferase activities. No recombinant UGT isoform exhibited detectable nicotine N-glucuronide nor cotinine N-glucuronide formations.
Inhibitory Effects of Typical Substrates for UGT Isoforms on Nicotine and Cotinine N-Glucuronidations in Human Liver Microsomes. The effects of bilirubin (UGT1A1), estradiol (UGT1A1 and UGT1A9), imipramine (UGT1A3 and UGT1A4), 4-nitrophenol (UGT1A6 and UGT1A9), propofol (UGT1A9), and morphine (UGT2B7) on nicotine and cotinine N-glucuronidations in pooled human liver microsomes were determined. Furthermore, the inhibitory effects of cotinine on nicotine N-glucuronidation and those of nicotine on cotinine N-glucuronidation in human liver microsomes were also determined. Nicotine N-glucuronidation in the pooled human liver microsomes was inhibited by bilirubin (IC50 = 1.9 µM), propofol (IC50 = 13.4 µM), estradiol (IC50 = 45.0 µM), and imipramine (IC50 = 48.3 µM). The inhibitory effects of 4-nitrophenol (IC50 = 84.0 µM), morphine (IC50 > 1 mM), and cotinine (IC50 > 1 mM) were not prominent. Cotinine N-glucuronidation in the pooled human liver microsomes was inhibited by bilirubin (IC50 = 1.6 µM), imipramine (IC50 = 2.4 µM), propofol (IC50 = 14.2 µM), estradiol (IC50 = 52.7 µM), and nicotine (IC50 = 74.5 µM). The inhibitory effects of 4-nitrophenol could not be determined because of the interference from the peak of cotinine N-glucuronide. The effects of morphine were not prominent (IC50 > 1 mM).
The Ki value and inhibitory type of bilirubin, imipramine, and propofol for nicotine and cotinine in human liver microsomes were determined. As shown in Fig. 2A, C, and E, nicotine N-glucuronidation in pooled human liver microsomes was competitively inhibited by bilirubin (Ki = 3.9 µM), imipramine (Ki = 6.1 µM), and propofol (Ki = 6.0 µM). Cotinine N-glucuronidation in pooled human liver microsomes was also competitively inhibited by bilirubin (Ki = 3.3 µM), imipramine (Ki = 2.7 µM), and propofol (Ki = 12.0 µM) (Fig. 2, B, D, and F).
|
Interindividual Variability of Nicotine and Cotinine N-Glucuronidations in Human Liver Microsomes. Nicotine N-glucuronidation activities in microsomes from 14 human livers ranged from 3.3 to 71.1 pmol/min/mg, representing ~22-fold variability (Fig. 3A). Cotinine N-glucuronidation activities in microsomes from 14 human livers ranged from 3.5 to 310.1 pmol/min/mg, representing ~89-fold variability (Fig. 3B).
|
Correlation Analyses. As shown in Table 3, the nicotine N-glucuronidation activities in liver microsomes from 14 humans were significantly correlated with the cotinine N-glucuronidation activities (r = 0.950, P < 0.001). Weak correlations between imipramine N-glucuronidation and nicotine N-glucuronidation (r = 0.425) or cotinine N-glucuronidation (r = 0.517) were observed, although these were not statistically significant. The imipramine N-glucuronidation activity measured in the present study was significantly correlated with the trifluoperazine glucuronidation activities provided by the manufacturer (r = 0.816, P < 0.005). The nicotine and cotinine N-glucuronidation activities did not correlate with the estradiol (UGT1A1), trifluoperazine (UGT1A4), and propofol (UGT1A9) glucuronidations (Table 3).
|
| |
Discussion |
|---|
|
|
|---|
The glucuronidations of nicotine and cotinine are important
metabolic pathways of nicotine in humans. It has been reported that the
percentages of nicotine N-glucuronide and cotinine
N-glucuronide excreted in urine were quite variable among
smokers (Benowitz et al., 1994
; Byrd et al., 2000
). This considerable
interindividual variability in nicotine and cotinine
N-glucuronidations would be one of the factors in the large
interindividual differences in nicotine metabolism. In the present
study, the nicotine and cotinine N-glucuronidations in human
liver microsomes were thoroughly characterized.
In our preliminary study, the nicotine and cotinine
N-glucuronidations in human liver microsomes were determined
at pH 7.4, 8.0, and 8.4 in 20 mM Tris-HCl buffer. However, no effects
of the pH were observed, although Ghosheh et al. (2001)
recently reported that nicotine N-glucuronidation was dramatically
increased 6-fold over a pH range of 7.4 to 8.4. In contrast, we
experienced that high concentrations of salt (100 mM Tris-HCl and 10 mM
MgCl2) decreased the formations of nicotine
N-glucuronide and cotinine N-glucuronide by about
50%. Therefore, the formations of nicotine N-glucuronide or
cotinine N-glucuronide in human liver microsomes were
determined at pH 7.4 with 20 mM Tris-HCl and 5 mM
MgCl2 in the present study. Very recently, it has
been reported that the kinetics of nicotine
N-glucuronidation in human liver microsomes was monophasic
with a Km value of 0.11 ± 0.017 mM (Ghosheh et al., 2001
). However, in our study, the kinetics was
clearly biphasic, indicating the involvement of multiple enzymes.
Differences between the assay conditions of their method (50 mM
Tris-HCl, pH 8.4, 5 mM MgCl2, 10 µg/ml
alamethicin, and 2 mM UDP-glucuronic acid in their assay) and those of
the present study might affect the kinetic profile of nicotine
N-glucuronidation.
It has been reported that the extent of conjugation of nicotine and
cotinine excreted in urine was highly correlated in an in vivo study
(Benowitz et al., 1994
). The present study is the first to show the
highly significant correlation between nicotine N-glucuronidation and cotinine N-glucuronidation
in human liver microsomes in an in vitro study. These results suggest
that the same enzymes are involved in the glucuronidations of nicotine and cotinine. It has been reported that the
N-glucuornidations of tertiary amines are catalyzed by
UGT1A3 and UGT1A4 (Green et al., 1995
; Green and Tephly, 1998
).
However, it is somewhat doubtful whether UGT1A3 makes a significant
contribution to the overall metabolism of tertiary amines because of
the higher apparent Km values and
lower expression in human liver compared with UGT1A4 (Green and Tephly,
1998
). Until now, it has been uncertain whether UGTs other than UGT1A3
and UGT1A4 catalyze the N-glucuronidation of tertiary
amines. However, in the present study, the nicotine and cotinine
N-glucuronidations in human liver microsomes were competitively inhibited by bilirubin, imipramine, and propofol, indicating the involvement of UGT1A1, UGT1A4, and UGT1A9. This is the
first report that UGT1A1 and UGT1A9 possibly catalyze the N-glucuronidation of tertiary amines. The nicotine and
cotinine N-glucuronidations were weakly correlated with the
imipramine N-glucuronidation catalyzed by mainly UGT1A4
rather than with glucuronidations of estradiol and propofol. Therefore,
it was considered that some contributions of UGT1A1 and UGT1A9 to the nicotine and cotinine N-glucuronidations might decrease the
correlation coefficients with imipramine N-glucuronidation.
The trifluoperazine glucuronidation is also considered to be catalyzed
by UGT1A4 (Green and Tephly, 1996
) and is significantly correlated with
imipramine N-glucuronidation (r = 0.816, P < 0.005). The reason that there were no correlations
between the nicotine or cotinine N-glucuronidations and the
trifluoperazine glucuronidation is unknown.
To identify the UGT isoform(s) involved in nicotine and cotinine
N-glucuronidations, the activities of recombinant UGTs
expressed in human B-lymphoblastoid cells or baculovirus-infected
insect cells that were commercially available were determined. However, no recombinant UGT isoform showed nicotine nor cotinine
N-glucuronidation. We confirmed that these recombinant UGTs
were active for other substrates such as imipramine and troglitazone
(Nakajima et al., 2002c
; Watanabe et al., 2002
). Therefore, it was
indicated that the turnovers of nicotine and cotinine
N-glucuronidations might be lower than those of other
substrates in these recombinant UGTs. Unfortunately, the contributions
of each UGT isoform to nicotine and cotinine
N-glucuronidation in human liver microsomes could not be
directly estimated. Furthermore, we recently reported that the all
recombinant UGTs did not exhibit the glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin, a major metabolite of phenytoin
(Nakajima et al., 2002
). In addition, we clarified that the morphine
3-glucuronosyltransferase activity in recombinant UGT2B7 was 25-fold
lower than that in the pooled in human liver microsomes (data not
shown). The differences in these glucuronosyltransferase activities
between the recombinant UGTs and human liver microsomes might be partly
due to the differences in the membrane circumstances in the expression
system and in human liver microsomes. Exactly, it has been reported
that the nature of the phopholipid environment influences the
rate-limiting step of glucuronidation (Magdalou et al., 1982
).
It has been reported that monoglucuronidation of phenols may by
catalyzed by a dimeric form of UGT, whereas diglucuronidation is
catalyzed by a tetramer (Gschaidmeier and Bock, 1994
). Homo-oligomer formation of rat UGT2B1 (Meech and Mackenzie, 1997
) and hetero-oligomer formation of rat UGT2B1 and UGT1A family (Ikushiro et al., 1997
) have
been reported. Recently, Ishii et al. (2001)
reported that hetero-oligomer formation of guinea pig UGT2B21 and UGT2B22 leads to
altered substrate specificity. In recombinant UGTs used in most
studies, including the present study, only homo-oligomers would be
formed. In the future studies, it is necessary to elucidate whether the
hetero-oligomers with many different combinations can exhibit the
catalytic activities of nicotine or cotinine glucuronidations by
double-transfection of different UGT cDNAs.
Large interindividual variability in nicotine
N-glucuronidation (~22 fold) and cotinine
N-glucuronidation (~89 fold) in human liver microsomes was
observed in the present study. Therefore, it is suggested that the
large interindividual differences in the percentages of glucuronide
conjugates excreted in urine were due to the interindividual
differences in the formations of these metabolites, i.e., the catalytic
properties of the UGT isoforms, rather than the process of excretion.
It has been reported that nicotine and cotinine
N-glucuronidations seemed to be polymorphic in
African-Americans, although these were unimodal in Caucasians (Benowitz
et al., 1999
). There are genetic polymorphisms in certain UGT isoforms,
i.e., UGT1A1, UGT1A6, UGT2B4, UGT2B7, and UGT2B15 (Tukey and
Strassburg, 2001
). A mutation in UGT1A4 has also been found, although
its clinical significance is unknown (Burchell et al., 1994
).
Therefore, the genetic polymorphisms in UGT1 isoforms might be a cause
of the interindividual differences in nicotine and cotinine
N-glucuronidation in humans. Furthermore, it has been
reported that UGT1A6 and UGT1A9 are inducible by polycyclic aromatic
hydrocarbons (PAHs) (Bock et al., 1999
). Cigarette smoke contains
abundant PAHs such as benzo[a]pyrene,
benz[a]anthrathene. Thus, the inducibility of UGTs
by PAHs in cigarette smoke might also be one of the causes of
interindividual differences in nicotine and cotinine
N-glucuronidations.
In conclusion, nicotine and cotinine N-glucuronidations in human liver microsomes were characterized thoroughly. The kinetics of nicotine N-glucuronidation in human liver microsomes was clearly biphasic, whereas that of cotinine N-glucuronidation was monophasic. Based on the highly significant correlation between the nicotine N-glucuronidation and cotinine N-glucuronidation in human liver microsomes, the same UGT isoform(s) might be involved in these glucuronidations. In addition to the contribution of UGT1A4 to the nicotine and cotinine N-glucuronidations in human liver microsomes, the involvement of UGT1A1 and UGT1A9 was also implicated.
| |
Acknowledgments |
|---|
We thank Brent Bell for reviewing this article.
| |
Footnotes |
|---|
Received August 10, 2002; accepted September 13, 2002.
This study was supported by a Smoking Research Foundation Grant for Biomedical Research in Japan, a grant from Japan Health Sciences Foundation with Research on Health Science focusing on Drug Innovation, and by Philip Morris Incorporated.
Address correspondence to: Miki Nakajima, Ph.D., Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Kanazawa University, Takara-machi 13-1, Kanazawa 920-0934, Japan. E-mail: nmiki{at}kenroku.kanazawa-u.ac.jp
| |
Abbreviations |
|---|
Abbreviations used are: UGT, UDP-glucuronosyltransferase; HPLC, high-performance liquid chromatography; PAH, polycyclic aromatic hydrocarbon.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
G. Chen, A. S. Blevins-Primeau, R. W. Dellinger, J. E. Muscat, and P. Lazarus Glucuronidation of Nicotine and Cotinine by UGT2B10: Loss of Function by the UGT2B10 Codon 67 (Asp>Tyr) Polymorphism Cancer Res., October 1, 2007; 67(19): 9024 - 9029. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kaivosaari, P. Toivonen, L. M. Hesse, M. Koskinen, M. H. Court, and M. Finel Nicotine Glucuronidation and the Human UDP-Glucuronosyltransferase UGT2B10 Mol. Pharmacol., September 1, 2007; 72(3): 761 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Kuehl, J. W. Lampe, J. D. Potter, and J. Bigler GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2005; 33(7): 1027 - 1035. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamanaka, M. Nakajima, M. Katoh, A. Kanoh, O. Tamura, H. Ishibashi, and T. Yokoi TRANS-3'-HYDROXYCOTININE O- AND N-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES Drug Metab. Dispos., January 1, 2005; 33(1): 23 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Staines, M. W. H. Coughtrie, and B. Burchell N-Glucuronidation of Carbamazepine in Human Tissues Is Mediated by UGT2B7 J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1131 - 1137. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Kuehl and S. E. Murphy N-GLUCURONIDATION OF NICOTINE AND COTININE BY HUMAN LIVER MICROSOMES AND HETEROLOGOUSLY EXPRESSED UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., November 1, 2003; 31(11): 1361 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuuranne, M. Kurkela, M. Thevis, W. Schanzer, M. Finel, and R. Kostiainen GLUCURONIDATION OF ANABOLIC ANDROGENIC STEROIDS BY RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., September 1, 2003; 31(9): 1117 - 1124. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||